Boosting Resiliency with Nicotinamide Riboside by Dr. Charles Brenner @EverythingALS
Boosting Resiliency with Nicotinamide Riboside by Dr. Charles Brenner  @EverythingALS
Uploaded August 2022 | Updated November 2026, 17 hours ago
Charles Brenner
PhD at Stanford University, Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism,

Charles Brenner is the Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism in the Department of Diabetes & Cancer Metabolism. His laboratory focuses on disturbances in nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism, in diseases and conditions of metabolic stress.

Among his most significant discoveries, he identified nicotinamide riboside (NR) as an unanticipated vitamin precursor of NAD. He also developed a quantitative metabolomic technology that allowed him and others to discover that the NAD system is disturbed by many diseases and conditions including diabetes, cancer and amyotrophic lateral sclerosis (ALS).

In this talk, Brenner will review what NAD is and does, what it known about disturbance of NAD systems in ALS and what data from mice and early stage clinical trials may mean for people living with ALS.
Boosting Resiliency with Nicotinamide Riboside by Dr. Charles BrennerPatient & Stakeholder Involvement in Clinical Research | Citizen ResearchBCI and ALS - Augmented Reality for people with ALS by Terry Heiman-PatersonDress with Success While Living with ALSUsing Stem Cells to Model and Treat ALS by Dr. Clive SvendsenWhats Old is New Again:Role of the Innate Immunity and its Biomarkers in ALSDr. Ostrow discusses precision medicine in ALSNew breakthroughs with NUROs second generation neurotechnologies by Mr. FrancoisWelcome 2023!  Year in Review: 2022 Highlights 🎉Technology for ALS Living and Voice BankingALS: Update in Treatment & Clinical TrialsThoughts on Clinical Trials from the Perspectives of an ALS Center Director
Everything ALS |

Boosting Resiliency with Nicotinamide Riboside by Dr. Charles Brenner

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER